In preclinical studies, it is reported that inhibitors targeting mutated forms of IDH1 and IDH2 can inhibit the growth of glioma cells and induce the differentiation of primary human IDH mutant AML cells in vitro (67). Here, IDH2 is linked to acute myeloid leukemia.